Cost-Effectiveness of Optimizing Use of Statins in Australia: Using Outpatient Data From the REACH Registry

Clinical Therapeutics

Volumn 33, Issue 10, 2011, Pages 1456-1465

  Ademi, Zanfina ^a,b   Reid, Christopher M ^b   Hollingsworth, Bruce ^b   Stoelwinder, Johannes ^b   Steg, Ph Gabriel ^c   Bhatt, Deepak L ^d,e   Vale, Margarite ^a   Liew, Danny ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c INSERM   (France)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Coronary artery disease; Cost effectiveness analysis; Registries; Statins

Indexed keywords

STATIN;

ARTICLE; AUSTRALIA; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG UTILIZATION; FEMALE; HEALTH CARE COST; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MALE; PROPHYLAXIS; REACTION OPTIMIZATION; RECURRENT DISEASE; REIMBURSEMENT; RISK REDUCTION; STROKE;

AMBULATORY CARE; AUSTRALIA; CORONARY ARTERY DISEASE; COST-BENEFIT ANALYSIS; DECISION TREES; DRUG UTILIZATION REVIEW; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMIC; REGISTRIES; SECONDARY PREVENTION;

EID: 80054948910     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.08.004     Document Type: Article

References (47)

1. Afilalo J., Duque G., Steele R., et al. Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis. J Am Coll Cardiol 2008, 51:37-45.
2. Franco O.H., Peeters A., Looman C.W., Bonneux L. Cost effectiveness of statins in coronary heart disease. J Epidemiol Comm Health 2005, 59:927-933.
3. Shalev V., Chodick G., Silber H., et al. Continuation of statin treatment and all-cause mortality. Arch Intern Med 2009, 169:260-268.
4. Revised PBS criteria for lipid-modifying drugs (October 2006) Accessed March 3, 2011. http://www.nps.org.au/health_professionals/publications/nps_radar/2007/february_2007/pbs_lmd_criteria.
5. Ohsfeldt R., Gandhi S., Fox K., McKenney J. Statin cost-effectiveness comparisons using real-world effectiveness data: formulary implications. Value Health 2008, 11:1061-1069.
6. Chodick G., Shalev V., Gerber Y., et al. Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel. Clin Ther 2008, 30:2167-2179.
7. Kesselheim A.S., Misono A.S., Lee J.L., et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA 2008, 300:2514-2526.
8. Reducing risk in heart disease 2007 (updated 2008) National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand, Accessed February 2, 2009. http://www.heartfoundation.org.au/SiteCollectionDocuments/Reduce-risk-in-heart-disease-guideline.pdf.
9. Heart and Stroke Facts: Statistical Update. Update At-a-Glance 2007, American Heart Association, American Heart Association, Dallas, Tex.
10. Annemans L., Marbaix S., Webb K., et al. Cost effectiveness of atorvastatin in patients with type 2 diabetes mellitus: a pharmacoeconomic analysis of the collaborative atorvastatin diabetes study in the belgian population. Clin Drug Investig 2010, 30:133-142.
11. Kang H., Ko S., Liew D. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions. Clin Ther 2009, 31:2919-2930.
12. Bhatt D.L., Steg P.G., Ohman E.M., et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006, 295:180-189.
13. Stocks N.P., Ryan P., McElroy H., Allan J. Statin prescribing in Australia: socioeconomic and sex differences. A cross-sectional study. Med J Aust 2004, 180:229-231.
14. Lim S., Vos T., Peeters A., et al. Cost-effectiveness of prescribing statins according to pharmaceutical benefits scheme criteria. Med J Aust 2001, 17:459-464.
15. Alberts M., Bhatt D., Mas J., et al. Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry. Eur Heart J 2009, 30:2318-2326.
16. Steg P.G., Bhatt D.L., Wilson P.W., et al. One-Year Cardiovascular Event Rates in Outpatients With Atherothrombosis. JAMA 2007, 297:1197-1206.
17. Christensen K., Doblhammer G., Rau R., Vaupel J.W. Ageing populations: the challenges ahead. Lancet 2009, 374:1196-1208.
18. Mahoney E.M., Wang K., Cohen D.J., et al. One-year costs in patients with history of or at risk for atherothrombosis in the United States. Circ Cardiovasc Qual Outcomes 2008, 1:38-45.
19. Ademi Z., Liew D., Hollingsworth B., et al. The economic implications of treating atherothrombotic disease in Australia, from the government perspective. Clin Ther 2010, 32:119-132.
20. Kauf T.L., Velazquez E.J., Crosslin D.R., et al. The cost of acute myocardial infarction in the new millennium: evidence from a multinational registry. Am Heart J 2006, 151:206-212.
21. Orlewska E., Budaj A., Tereszkowski-Kaminski D. Cost-effectiveness analysis of enoxaparin versus unfractionated heparin in patients with acute coronary syndrome in Poland: modelling study from the hospital perspective. Pharmacoeconomics 2003, 21:737-748.
22. Garrison L.P., Neumann P.J., Erickson P., et al. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force Report. Value Health 2007, 10:326-335.
23. Joel W.H., Jim S., Norman V.C., et al. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force Report-Part I. Value Health 2009, 13:3-7.
24. Briggs A., Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998, 13:397-409.
25. Reid C., Nelson M.R., Shiel L., et al. Australians at risk: management of cardiovascular risk factors in the REACH Registry. Heart Lung Circulation 2008, 17:114-118.
26. Medicare Australia, Accessed April 11, 2010. http://www.medicareaustralia.gov.au/.
27. Public Sector Estimated Cost Weights Round 12 AR-DRG v5.1 (Excel 276 KB) Accessed June 3, 2010. http://www.health.gov.au/internet/main/publishing.nsf/Content/Round_12-cost-reports.
28. Duckett S.J. The Australian Health Care System 2007, Oxford University Press, South Melbourne, Australia. 3rd ed.
29. Australian Institute of Health and Welfare (AIHW), Accessed May 2, 2011. http://www.aihw.gov.au/.
30. Liew D, Vale M, Jelinek M, et al. The COACH program is cost-effective for the secondary prevention of coronary heart disease. Poster presented at: ESC Congress; August 28-September 1, 2010; Stockholm, Sweden.
31. Jelinek M., Vale M.J., Liew D., et al. The COACH Program Produces Sustained Improvements in Cardiovascular Risk Factors and Adherence to Recommended Medications-two years follow-up. Heart Lung Circulation 2009, 18:388-392.
32. Severens J.L., Milne R.J. Discounting health outcomes in economic evaluation: the ongoing debate. Value Health 2004, 7:397-401.
33. O'Hagan A., McCabe C., Akehurst R., et al. Incorporation of uncertainty in health economic modelling studies. Pharmacoeconomics 2005, 23:529-536.
34. Gafni A., Birch S. Incremental cost-effectiveness ratios (ICERs): the silence of the lambda. Social Science Med 2006, 62:2091-2100.
35. Ademi Z., Walls H.L., Peeters A., Liew D., et al. Economic implications of obesity among people with atherothrombotic disease. Int J Obes (Lond) 2010, 34:1284-1292.
36. New Zealand Pharmaceutical Schedule April 2010, Accessed: June 1, 2010. http://www.pharmac.govt.nz.
37. British National Formulary, 59 Accessed June 5, 2010. http://www.medicinescomplete.com/mc/bnf/current/.
38. Searles A., Jefferys S., Doran E., Henry D.A. Reference pricing, generic drugs and proposed changes to the Pharmaceutical Benefits Scheme. Med J Aust 2007, 187:236-239.
39. Kanavos P., Font J. Generic Competition in Drug Markets and the Impact of Regulation. Forthcoming as Discussion Paper LSE Health October 2006.
40. Kanavos P., Costa-Font J., Frank R. Exploring the nature of generic competition in 7 industrialised countries, LSE Health Discussion Paper 2007.
41. Henry D., Hill S., Harris A. Drug prices and value for money: the Australian Pharmaceutical Benefits Scheme. JAMA 2005, 294:2630-2632.
42. Pasternak R.C., Smith S.C., Bairey-Merz C.N., et al. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation 2002, 106:1024-1028.
43. Simons L.A., Ortiz M., Calcino G. Persistence with antihypertensive medication: Australia-wide experience, 2004-2006. Med J Aust 2008, 188:224-227.
44. Bhatt D., Eagle K., Ohman M., et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA 2010, 304:1350-1357.
45. Vale M.J., Jelinek M.V., Best J.D., et al. Coaching patients on achieving cardiovascular health (COACH)-a multicenter randomized trial in patients with coronary heart disease. Arch Intern Med 2003, 163:2775-2783.
46. Dormuth C.R., Patrick A.R., Shrank W.H., et al. Statin adherence and risk of accidents: a cautionary tale. Circulation 2009, 119:2051-2057.
47. Schedule of Pharmaceutical Benefits for approved pharmacists and medical practitioners 2011 Accessed February 6, 2011. http://www.pbs.gov.au/browse/medicine-listing.